Skip to main content
. 2017 Jan 23;12(1):e0170291. doi: 10.1371/journal.pone.0170291

Fig 4. IFN-γ ELISpot assay using tumor-infiltrating lymphocytes (TILs) against one of the SART3-derived peptides (SART3109) in HCC patients.

Fig 4

ELISpot was performed in eight patients from whom samples of both PBMCs and TILs could be obtained. Open and solid bars show the frequency of SART3-specific T cells in PBMCs and TILs, respectively.